ALAUNOS THERAPEUTICS INC (TCRT) Stock Price, Forecast & Analysis
USA - NASDAQ:TCRT - US98973P3091 - Common Stock
TCRT Key Statistics, Chart & Performance
The current stock price of TCRT is 2.88 USD. In the past month the price decreased by -22.39%. In the past year, price increased by 21.05%.
TCRT Latest News, Press Relases and Analysis
TCRT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.73 | 396.13B | ||
| AMGN | AMGEN INC | 15.3 | 180.12B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 151.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.5 | 109.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.87 | 70.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888.4 | 59.39B | ||
| INSM | INSMED INC | N/A | 40.59B | ||
| NTRA | NATERA INC | N/A | 28.57B | ||
| BIIB | BIOGEN INC | 9.4 | 23.07B | ||
| INCY | INCYTE CORP | 16.77 | 21.03B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.54 | 20.94B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.05 | 14.53B |
Related stock screener links
About TCRT
Company Profile
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Company Info
ALAUNOS THERAPEUTICS INC
501 E Las Olas Blvd, Suite 300
FORT LAUDERDALE FLORIDA US
Employees: 1
Phone: 13463554099
ALAUNOS THERAPEUTICS INC / TCRT FAQ
What does ALAUNOS THERAPEUTICS INC do?
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
What is the current price of TCRT stock?
The current stock price of TCRT is 2.88 USD. The price increased by 13.83% in the last trading session.
Does TCRT stock pay dividends?
TCRT does not pay a dividend.
How is the ChartMill rating for ALAUNOS THERAPEUTICS INC?
TCRT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for TCRT stock?
ALAUNOS THERAPEUTICS INC (TCRT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.46).
Is ALAUNOS THERAPEUTICS INC (TCRT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCRT.
When does ALAUNOS THERAPEUTICS INC (TCRT) report earnings?
ALAUNOS THERAPEUTICS INC (TCRT) will report earnings on 2025-11-12.
TCRT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TCRT. When comparing the yearly performance of all stocks, TCRT is one of the better performing stocks in the market, outperforming 80.03% of all stocks.
TCRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRT. No worries on liquidiy or solvency for TCRT as it has an excellent financial health rating, but there are worries on the profitability.
TCRT Financial Highlights
Over the last trailing twelve months TCRT reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS decreased by -34.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.33% | ||
| ROE | -109.07% | ||
| Debt/Equity | 0 |